U.S. Food and Drug Administration has approval on April 15th Tuesday .(Health day) of a once-weekly injectable drug, Tanzeum.
Tanzeum is injected once a week and appears to help control blood sugar levels.
The FDA described Tanzeum (albiglutide) as a "glucagon-like peptide-1 (GLP-1) receptor agonist -- a hormone that helps normalize patients' blood sugar.
Tanzeum "can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes per FDA.
The FDA's approval of the drug was based on eight clinical trials that included more than 2,000 people with type 2 diabetes. Those who took Tanzeum showed improvements in blood sugar control. The drug has also been studied for use in combination with other diabetes medications such as metformin, glimipride etc.
The most common side effects seen with Tanzeum were nausea and/or reactions at the site of injection, the FDA said.
As per FDA ,Post-marketing clinical trials are planned to examine cardiovascular effects, use in pediatric patients, and possible increase in pancratities or medullary thyroid cancer," . "The results of these clinical trials will determine which GLP-1 agonists will be more useful" to patients.
For further reference please follow the link
For the information of the group